丙型肝炎治疗干预策略：现状与未来。

Strategies for hepatitis C therapeutic intervention: now and next.

作者信息

Tan Seng-Lai, He Yupeng, Huang Ying, Gale Michael

机构信息

Lilly Research Laboratories, Bldg 98A/2, Room 2105, Lilly Corporate Center, Indianapolis, IN 46285, USA.

出版信息

Curr Opin Pharmacol. 2004 Oct;4(5):465-70. doi: 10.1016/j.coph.2004.07.003.

DOI:10.1016/j.coph.2004.07.003

PMID:15351350

Abstract

Interferon-alpha-based therapies are the mainstay of hepatitis C treatment. However, these broad immunomodulatory agents, already limited by their side effects, expense and route of administration, are not efficacious in all cases. Therefore, research efforts have focused on identifying additional drugs and therapeutic modalities to benefit those individuals refractive to current therapy, and which might be more affordable, such as orally active small-molecule alternatives and preventive or therapeutic vaccines. It is likely that successful therapeutic intervention of hepatitis C will require a combination of approaches targeting different aspects of the viral life-cycle.

摘要

基于α干扰素的疗法是丙型肝炎治疗的主要手段。然而，这些广泛的免疫调节药物，已经受到其副作用、费用和给药途径的限制，并非在所有情况下都有效。因此，研究工作集中在确定其他药物和治疗方式，以使那些对当前治疗无效的个体受益，并且这些药物可能更具成本效益，例如口服活性小分子替代物以及预防性或治疗性疫苗。丙型肝炎的成功治疗干预可能需要针对病毒生命周期不同方面的多种方法的组合。